Fresenius Group Overview

Outlook

For 2017, Fresenius projects sales growth of 15% to 17% in constant currency.
Net income² is expected to grow by 19% to 21%³ in constant currency.

	Targets 2017¹	Fiscal year 2016¹
Fresenius Group
Sales, growth (in constant currency)	15% – 17%	€ 29,471 million
Net income², growth (in constant currency)	19% – 21%³	€ 1,560 million
Capital Expenditure	~ 6% of sales	€ 1,633 million
Dividend	Profit-driven dividend policy	Proposal: +13% per share
Fresenius Medical Care
Sales growth⁴ (in constant currency)	8% – 10%	€ 16,570 million
Net income^4,5, growth	7% – 9%	€ 1,144 million
Fresenius Kabi
Sales growth (organic)	5% – 7%	€ 6,007 million
EBIT (in constant currency)	6% – 8%³	€ 1,171 million
Fresenius Helios
Sales growth (organic)	3% – 5%⁶	€ 5,843 million⁶
Sales	~€8.6 billion^7,8	€ 5,843 million⁶
EBIT	€ 1,020 m – € 1,070 m⁷^,9	€ 683 million⁶
Fresenius Vamed
Sales growth (organic)	5% – 10%	€ 1,160 million
EBIT growth	5% – 10%	€ 69 million

¹All data according to IFRS
² Net income attributable to shareholders of Fresenius SE & Co. KGaA
³ Before transaction costs of ~€50 million for the acquisitions of Akorn, Inc. and Merck KGaA’s biosimilars business; before expected expenditures for the further development of Merck KGaA’s biosimilars business of ~€50 million (expected closing H2/17)
⁴ The effects of the agreement with the U.S. Department of Veterans Affairs and Justice are excluded
⁵ Net income attributable to shareholders of Fresenius Medical Care AG & Co. KGaA
⁶Helios Kliniken Germany, excluding Quirónsalud
⁷Quirónsalud 11 months consolidated
⁸ Thereof Quirónsalud: ~€2.5 billion
⁹ Thereof Quirónsalud: €300 to 320 million
As of May, 2017

Fresenius SE & Co. KGaA
Else-Kröner-Str. 1
61352 Bad Homburg v.d.H.
Germany
T +49 (0) 6172 608-0
pr-fre@fresenius.com

Contact